MetaCap

Jupiter Neurosciences (JUNS) vs PRF Technologies (PRFX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PRF Technologies is the larger company by market cap ($1.7 million vs $1.6 million), about 1.0 times the size. PRF Technologies converts more of its revenue into profit, with a net margin of -29541.2% versus -39662.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JUNS-56.51%PRFX-45.79%
+22%-19%-60%
Oct 7, 20261 yearNov 20, 2026
JUNS-56.67%PRFX-45.86%
+8%-26%-60%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JUNS versus PRFX key metrics
MetricJUNSPRFX
Share price$1.24$0.4758
Market cap$1.63M$1.66M
1-day change-18.75%-23.68%
Forward P/E20.58—
EPS (TTM)$-22.53$-4.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$21.80K$17.00K
Net income (latest FY)$-8.64M$-5.02M
Gross margin80.59%-311.76%
Operating margin-40873.19%-30129.41%
Net margin-39662.77%-29541.18%
52-week high$97.73$7.95
52-week low$1.20$0.46
Distance from 52-week high-98.74%-94.02%
Average volume69.86K228.55K
Shares outstanding1.32M3.50M
Employees56
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRF Technologies is more profitable, keeping -29541.2 cents of every revenue dollar as net income versus -39662.8 cents for Jupiter Neurosciences.

About Jupiter Neurosciences

JUNS stock →

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About PRF Technologies

PRFX stock →

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

JUNS vs PRFX FAQ

Which is bigger, Jupiter Neurosciences or PRF Technologies?

PRF Technologies (PRFX) is larger, with a market capitalization of $1.66M compared with $1.63M for Jupiter Neurosciences (JUNS).

Are Jupiter Neurosciences and PRF Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons